Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans

Hepatology International

Volumn 4, Issue 2, 2010, Pages 523-529

  Nguyen, Nghia H ^a,b   Vutien, Philip ^a,b   Trinh, Huy N ^a,c   Garcia, Ruel T ^a,c   Nguyen, Long H ^d   Nguyen, Huy A ^c   Nguyen, Khanh K ^c   Nguyen, Mindie H ^b  

^a Pacific Health Foundation   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c San Jose Gastroenterology   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Genotype 6; HCV; Risk factors; Southeast Asians

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; ASIAN AMERICAN; BLOOD TRANSFUSION; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; GENERAL SURGERY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VIROLOGY;

EID: 77955509605     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9181-7     Document Type: Article

References (30)

1. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 1999;74(49):425-427
2. C Mallette MA Flynn K Promrat 2008 Outcome of screening for hepatitis C virus infection based on risk factors Am J Gastroenterol 103 1 131 137 17894850
3. HB El-Serag 2002 Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 5 Suppl 1 S74 S83 10.1002/hep.1840360710 12407579
4. MM Hassan A Frome YZ Patt HB El-Serag 2002 Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States J Clin Gastroenterol 35 3 266 269 10.1097/00004836-200209000-00013 12192205 (Pubitemid 34913096)
5. GL Armstrong A Wasley EP Simard GM McQuillan WL Kuhnert MJ Alter 2006 The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 10 705 714 16702586
6. MH Nguyen EB Keeffe 2005 Chronic hepatitis C: genotypes 4 to 9 Clin Liver Dis 9 3 411 426 10.1016/j.cld.2005.05.010 16023974 vi (Pubitemid 40968204)
7. FX Bosch J Ribes J Borras 1999 Epidemiology of primary liver cancer Semin Liver Dis 19 3 271 285 10.1055/s-2007-1007117 1:STN:280:DyaK1Mvks1Gktw%3D%3D 10518307
8. FX Bosch J Ribes M Diaz R Cleries 2004 Primary liver cancer: worldwide incidence and trends Gastroenterology 127 5 Suppl 1 S5 S16 10.1053/j.gastro. 2004.09.011 15508102 (Pubitemid 39423365)
9. DS Chen 2007 Hepatocellular carcinoma in Taiwan Hepatol Res 37 Suppl 2 S101 S105 10.1111/j.1872-034X.2007.00170.x 17877468
10. T Umemura T Ichijo K Yoshizawa E Tanaka K Kiyosawa 2009 Epidemiology of hepatocellular carcinoma in Japan J Gastroenterol 44 Suppl 19 102 107 10.1007/s00535-008-2251-0 19148802
11. BJ Veldt EJ Heathcote H Wedemeyer J Reichen WP Hofmann S Zeuzem, et al. 2007 Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 10 677 684 18025443
12. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39
13. MJ Alter LB Seeff BR Bacon DL Thomas MO Rigsby AM Di Bisceglie 2004 Testing for hepatitis C virus infection should be routine for persons at increased risk for infection Ann Intern Med 141 9 715 717 15520428
14. CP Li SJ Hwang CL Lu CY Chan JC Wu FY Lee, et al. 1996 Risk factor analysis of patients with chronic hepatitis C in Taiwan Zhonghua Yi Xue Za Zhi (Taipei) 58 4 275 280 1:STN:280:DyaK2s7kslCmtA%3D%3D
15. Y Ngo S Maugat QT Duong TN Nguyen P Astagneau 2007 Risk of hepatitis C related to traditional medicine: a case control study in Ho Chi Minh City, Vietnam Rev Epidemiol Sante Publ 55 2 107 112 1:STN:280:DC%2BD2szjvFOntw%3D%3D
16. JT Cheng C Hsien HE Sun MJ Tong 2006 The emerging importance of chronic hepatitis C infection in Asian Americans Am J Gastroenterol 101 12 2737 2743 10.1111/j.1572-0241.2006.00831.x 17227521 (Pubitemid 44902645)
17. A Dev V Sundararajan W Sievert 2004 Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition J Gastroenterol Hepatol 19 7 792 798 10.1111/j.1440-1746.2004.03381.x 15209627 (Pubitemid 38981402)
18. AT Dev R McCaw V Sundararajan S Bowden W Sievert 2002 Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome Hepatology 36 5 1259 1265 10.1053/jhep.2002.36781 12395338 (Pubitemid 35253444)
19. J Fung CL Lai I Hung J Young C Cheng D Wong, et al. 2008 Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin J Infect Dis 198 6 808 812 10.1086/591252 1:CAS:528:DC%2BD1cXhtFygs7rF 18657036
20. CK Hui MF Yuen E Sablon AO Chan BC Wong CL Lai 2003 Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1 J Infect Dis 187 7 1071 1074 10.1086/368217 1:CAS:528: DC%2BD3sXjtlektbY%3D 12660921 (Pubitemid 36399349)
21. MH Nguyen HN Trinh R Garcia G Nguyen KD Lam EB Keeffe 2008 Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin Am J Gastroenterol 103 5 1131 1135 10.1111/j.1572-0241.2008.01793.x 1:CAS:528:DC%2BD1cXntFCku7w%3D 18477343 (Pubitemid 351677993)
22. J Bukh RH Purcell RH Miller 1994 Sequence analysis of the core gene of 14 hepatitis C virus genotypes Proc Natl Acad Sci USA 91 17 8239 8243 10.1073/pnas.91.17.8239 1:CAS:528:DyaK2cXmslensL4%3D 8058787 (Pubitemid 24253922)
23. L Stuyver A Wyseur W van Arnhem F Hernandez G Maertens 1996 Second-generation line probe assay for hepatitis C virus genotyping J Clin Microbiol 34 9 2259 2266 1:STN:280:DyaK2s%2FhsF2mug%3D%3D 8862595
24. MJ Alter 2002 Prevention of spread of hepatitis C Hepatology 36 5 Suppl 1 S93 S98 10.1002/hep.1840360712 12407581
25. GL Davis JY Lau 1997 Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 3 Suppl 1 122S 1227S 10.1002/hep.510260721 1:CAS:528:DyaK2sXmt1CktLw%3D 9305676
26. M Martinot-Peignoux P Marcellin M Pouteau C Castelnau N Boyer M Poliquin, et al. 1995 Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C Hepatology 22 4 Pt 1 1050 1056 10.1002/hep.1840220406 1:CAS:528:DyaK2MXptl2jsrc%3D 7557850
27. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 21 1485 1492 10.1056/NEJM199811193392101 1:CAS:528:DyaK1cXnslGmtbs%3D 9819446 (Pubitemid 28543496)
28. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo, et al. 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 9138 1426 1432 10.1016/S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D 9807989 (Pubitemid 28510876)
29. Dunglison R. Medical Lexicon: a Dictionary of Medical Science. 15th ed. Philadelphia: Blanchard and Lea; 1857. 992
30. Nguyen V, McLaws M, Dore G. Prevalence and risk factors for hepatitis C infection in rural north Vietnam. Hepatol Int 2007;1(3):387-393